Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206995347> ?p ?o ?g. }
- W4206995347 endingPage "125" @default.
- W4206995347 startingPage "111" @default.
- W4206995347 abstract "Angiogenesis, the formation of new capillaries from preexisting blood vessels, plays an important role in cancer progression. When the tumor mass expands, the balance is shifted toward a pro-angiogenic milieu to maintain sustainable angiogenic processes. In this context, there is an up-regulation of several pro-angiogenic factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), placental growth factor (PlGF), platelet derived endothelial cell growth factor (PD-ECGF), angiopoietins (Angs), transforming growth factors (TGFs) -α and -β, and epidermal cell growth factor (EGF), which collectively activate the proliferation of circulating endothelial progenitor cells (EPCs) able to enter in the peripheral blood circulation, migrating to sites of angiogenesis. Hence, the number of antiangiogenic agents developed for cancer treatment has risen over the past years. To date, the most common approaches to the inhibition of the VEGF axis include the blockade of VEGF receptors (VEGFRs) or ligands by neutralizing antibodies, as well as the tyrosine kinase inhibitors (TKIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs). Here, we focus on the role of circulating EPCs, which mediate the cross-talk between cancer angiogenesis and neoplastic clone, as potential novel targets for antiangiogenic drugs with particular relevance for hematological malignancies." @default.
- W4206995347 created "2022-01-26" @default.
- W4206995347 creator A5012195468 @default.
- W4206995347 creator A5018348844 @default.
- W4206995347 creator A5038350233 @default.
- W4206995347 creator A5054370212 @default.
- W4206995347 creator A5074410725 @default.
- W4206995347 creator A5079098718 @default.
- W4206995347 creator A5085863516 @default.
- W4206995347 date "2022-01-01" @default.
- W4206995347 modified "2023-09-25" @default.
- W4206995347 title "Antiangiogenic drugs as chemosensitizers in hematological tumors" @default.
- W4206995347 cites W1485875137 @default.
- W4206995347 cites W1539571840 @default.
- W4206995347 cites W1543678657 @default.
- W4206995347 cites W1601856726 @default.
- W4206995347 cites W1970107343 @default.
- W4206995347 cites W1973888964 @default.
- W4206995347 cites W1980068016 @default.
- W4206995347 cites W1982861439 @default.
- W4206995347 cites W1985147506 @default.
- W4206995347 cites W1988476050 @default.
- W4206995347 cites W1988605844 @default.
- W4206995347 cites W1992112921 @default.
- W4206995347 cites W1994327661 @default.
- W4206995347 cites W2006202974 @default.
- W4206995347 cites W2010570442 @default.
- W4206995347 cites W2011413594 @default.
- W4206995347 cites W2011765548 @default.
- W4206995347 cites W2014892762 @default.
- W4206995347 cites W2020778579 @default.
- W4206995347 cites W2021221402 @default.
- W4206995347 cites W2022234182 @default.
- W4206995347 cites W2022540958 @default.
- W4206995347 cites W2026042590 @default.
- W4206995347 cites W2037775640 @default.
- W4206995347 cites W2037834319 @default.
- W4206995347 cites W2044098233 @default.
- W4206995347 cites W2052223356 @default.
- W4206995347 cites W2056392579 @default.
- W4206995347 cites W2059958205 @default.
- W4206995347 cites W2060469376 @default.
- W4206995347 cites W2061478772 @default.
- W4206995347 cites W2067379331 @default.
- W4206995347 cites W2072137391 @default.
- W4206995347 cites W2089030718 @default.
- W4206995347 cites W2091447224 @default.
- W4206995347 cites W2098282622 @default.
- W4206995347 cites W2101037339 @default.
- W4206995347 cites W2104300873 @default.
- W4206995347 cites W2116619860 @default.
- W4206995347 cites W2116685321 @default.
- W4206995347 cites W2117692326 @default.
- W4206995347 cites W2119810076 @default.
- W4206995347 cites W2126088749 @default.
- W4206995347 cites W2127872440 @default.
- W4206995347 cites W2129880070 @default.
- W4206995347 cites W2136236544 @default.
- W4206995347 cites W2141487097 @default.
- W4206995347 cites W2143852804 @default.
- W4206995347 cites W2146001019 @default.
- W4206995347 cites W2149456801 @default.
- W4206995347 cites W2150763257 @default.
- W4206995347 cites W2158794607 @default.
- W4206995347 cites W2168929741 @default.
- W4206995347 cites W2171568102 @default.
- W4206995347 cites W2171777802 @default.
- W4206995347 cites W2255518001 @default.
- W4206995347 cites W2397214528 @default.
- W4206995347 cites W2489477621 @default.
- W4206995347 cites W2770619558 @default.
- W4206995347 cites W2779325841 @default.
- W4206995347 cites W2791152679 @default.
- W4206995347 cites W2801437776 @default.
- W4206995347 cites W2804658899 @default.
- W4206995347 cites W2834234875 @default.
- W4206995347 cites W3013347515 @default.
- W4206995347 cites W3102699168 @default.
- W4206995347 cites W4230026896 @default.
- W4206995347 cites W4230886463 @default.
- W4206995347 doi "https://doi.org/10.1016/b978-0-323-90190-1.00010-x" @default.
- W4206995347 hasPublicationYear "2022" @default.
- W4206995347 type Work @default.
- W4206995347 citedByCount "0" @default.
- W4206995347 crossrefType "book-chapter" @default.
- W4206995347 hasAuthorship W4206995347A5012195468 @default.
- W4206995347 hasAuthorship W4206995347A5018348844 @default.
- W4206995347 hasAuthorship W4206995347A5038350233 @default.
- W4206995347 hasAuthorship W4206995347A5054370212 @default.
- W4206995347 hasAuthorship W4206995347A5074410725 @default.
- W4206995347 hasAuthorship W4206995347A5079098718 @default.
- W4206995347 hasAuthorship W4206995347A5085863516 @default.
- W4206995347 hasConcept C126322002 @default.
- W4206995347 hasConcept C130287650 @default.
- W4206995347 hasConcept C167734588 @default.
- W4206995347 hasConcept C170493617 @default.
- W4206995347 hasConcept C203014093 @default.
- W4206995347 hasConcept C2775960820 @default.